Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Harvard and Servier sign microbiome research pact
by Lisa M. Jarvis
March 29, 2019
| A version of this story appeared in
Volume 97, Issue 13
Servier and Harvard University have signed a three-year pact to research and develop microbiome-targeting therapeutics for the treatment of type 2 diabetes and nonalcoholic fatty liver disease. Harvard professor Emily Balskus, an expert in the chemistry of the gut microbiome, will be the academic project leader, while the French drugmaker will contribute knowledge in metabolism and drug development. The project stems from a 2017 research alliance under which Harvard professors can submit proposals for possible Servier funding.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X